Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.
AMGN
$417.30
-$0.54 -0.13%

BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.

Market News
11 Aug 2026
24/7 Wall Street
View Source
Bullish
pluang ai news

BioCryst Pharmaceuticals reported its first full year of profitability in 2025 and posted $218.25 million in revenue for Q2 2026, a 33.6% increase year-over-year. The company, known for its rare disease drug Orladeyo, which generated $158.2 million in Q2 revenue, is attracting takeover speculation following its acquisition of Astria Therapeutics earlier in 2026. Potential strategic buyers include Takeda, AstraZeneca, and others, though private equity interest is lower due to BioCryst's debt and obligations. Investors are watching for upcoming data on navenibart, a promising injectable drug, and any acquisition moves.

More News (AMGN)

Wave Life Sciences shares drop amid strategic buyout speculation on RNA-medicine assets.

Wave Life Sciences shares drop amid strategic buyout speculation on RNA-medicine assets.

Wave Life Sciences shares are down significantly this year, trading near their 52-week low with a market cap around $1 billion. The company, focused on RNA-based medicines, holds substantial cash but is currently unprofitable. Its key assets include ...

Market News
Bullish
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App